<http://webisa.webdatacommons.org/prov/503844210>	<http://www.w3.org/ns/prov#wasDerivedFrom>	<http://webisa.webdatacommons.org/4322728> .
<http://webisa.webdatacommons.org/4322728>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/prov#Entity> .
<http://webisa.webdatacommons.org/4322728>	<http://www.w3.org/ns/prov#wasQuotedFrom>	<in-pharmatechnologist.com> .
<http://webisa.webdatacommons.org/4322728>	<http://www.w3.org/ns/prov#value>	" areas such as oncology development, OTC manufacturing and supply chain management for its generics subsidiary Sandoz, the firm will cut up to 500 jobs to support this, mainly in headquarter support functions and in operational roles in pharmaceuticals development.However, Novartis says the overall headcount in Switzerland will remain stable, at around 15,000." .